PCV chemotherapy
Phase 3Small molecule
PCV chemotherapy is one of 10 small molecule programs targeting Oligodendroglioma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Oligodendroglioma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Verzenio
Eli LillyPhase 2
L19TNF
PPhilogen S.p.A.
Phase 2
PCV chemotherapy
HHospices Civils de Lyon
Phase 3
Tislelizumab Plus Bevacizumab
HHenan Provincial People's Hospital
Phase 2
Fluzone
SanofiPreclinical
Voranigo
SServier
Preclinical
TTRNA-DC Vaccines With GM-CSF
UUniversity of Florida
Phase 1
TTRNA-Xalt
UUniversity of Florida
Phase 1
Matulane
LLeadiant Biosciences, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PCV chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHospices Civils de Lyon